Vaxcyte $PCVX: Needham reiterated its Buy rating with a $110.00 price target.
https://fundspec.ai/s/PCVX/analysts
50+ fundamentals like ROIC and free cash flow yield, ranked against the whole market.
https://fundspec.ai/s/PCVX/analysts
50+ fundamentals like ROIC and free cash flow yield, ranked against the whole market.
September 25, 2026 at 10:45 AM
Vaxcyte $PCVX: Needham reiterated its Buy rating with a $110.00 price target.
https://fundspec.ai/s/PCVX/analysts
50+ fundamentals like ROIC and free cash flow yield, ranked against the whole market.
https://fundspec.ai/s/PCVX/analysts
50+ fundamentals like ROIC and free cash flow yield, ranked against the whole market.
🌖A new video-devlog for Moons in Crystal is up!🔮
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
Moons in Crystal--Video Devlog 6.5--"A Visual Update"
YouTube video by Ian Eborn
www.youtube.com
January 14, 2026 at 11:14 AM
🌖A new video-devlog for Moons in Crystal is up!🔮
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
🎨"A Visual Update"🧱
www.youtube.com/watch?v=pCvX...
#MoonsInCrystal #Metroidvania #IndieGame #IndieDev #GameDev #Devlog
My book: “Under the Shadows of Words”
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
February 28, 2026 at 4:42 PM
My book: “Under the Shadows of Words”
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
Here’s the link: online.fliphtml5.com/jwxyt/pcvx/
In case you're interested in reading it. You can read for free
@georgeyuhasz-7.bsky.social @norbaikin.bsky.social @mattstarrfineart.bsky.social @cathaguamia.bsky.social
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
September 25, 2026 at 8:15 PM
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
2/3 Nilesh KUMAR, Wellington Management: Avere Therapeutics, KRSA, MBX
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
September 25, 2026 at 8:45 PM
2/3 Nilesh KUMAR, Wellington Management: Avere Therapeutics, KRSA, MBX
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
September 3, 2024 at 6:45 PM
September 3, 2024 at 3:35 PM
September 3, 2024 at 5:25 PM
September 3, 2024 at 4:15 PM
Leur maison est squattée depuis 8 ans➡️ https://l.actu.fr/PCVx
June 18, 2026 at 4:16 PM
Leur maison est squattée depuis 8 ans➡️ https://l.actu.fr/PCVx
#trading #stock #premarket #AI #news
Stock Premarket - Mar 31, 2025
See StockQuakes.com
UP
↑ CORT Corcept 89.5%
↑ CTOR Citius Oncology 60.2%
↑ CERO Cero Therapeutics 35.2%
DOWN
↓ PCVX Vaxcyte, -30.9%
↓ RR Richtech -10.0%
↓ OKLO Oklo -7.9%
Stock Premarket - Mar 31, 2025
See StockQuakes.com
UP
↑ CORT Corcept 89.5%
↑ CTOR Citius Oncology 60.2%
↑ CERO Cero Therapeutics 35.2%
DOWN
↓ PCVX Vaxcyte, -30.9%
↓ RR Richtech -10.0%
↓ OKLO Oklo -7.9%
StockQuakes - AI Stock Analysis
Using AI to find stock market opportunities.
StockQuakes.com
March 31, 2025 at 12:38 PM
#trading #stock #premarket #AI #news
Stock Premarket - Mar 31, 2025
See StockQuakes.com
UP
↑ CORT Corcept 89.5%
↑ CTOR Citius Oncology 60.2%
↑ CERO Cero Therapeutics 35.2%
DOWN
↓ PCVX Vaxcyte, -30.9%
↓ RR Richtech -10.0%
↓ OKLO Oklo -7.9%
Stock Premarket - Mar 31, 2025
See StockQuakes.com
UP
↑ CORT Corcept 89.5%
↑ CTOR Citius Oncology 60.2%
↑ CERO Cero Therapeutics 35.2%
DOWN
↓ PCVX Vaxcyte, -30.9%
↓ RR Richtech -10.0%
↓ OKLO Oklo -7.9%
News; ( NASDAQ: #PCVX ) Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results
#StockMarket #News
#StockMarket #News
September 3, 2024 at 3:15 PM
BioPharmCatalyst Watchlist: Top biotech stocks to watch—key Phase 1/2 catalysts in the next 6 months. $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM www.biopharmcatalyst.com/news/2025/bi...
October 17, 2025 at 8:15 PM
BioPharmCatalyst Watchlist: Top biotech stocks to watch—key Phase 1/2 catalysts in the next 6 months. $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM www.biopharmcatalyst.com/news/2025/bi...
#PCVX Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-1j4rsdh8blrl.html
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-1j4rsdh8blrl.html
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte (Nasdaq: PCVX) reported Q1 2026 results and a business update. As of March 31, 2026, cash, cash equivalents and investments totaled $2.74 billion. Enrollment is complete for three VAX-31 adult Phase 3 OPUS trials (6,191 adults dosed). OPUS-1 topline data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027. Infant Phase 2 enrollment completed (900 infants); infant readouts expected by end of H1 2027. Company plans to start a Phase 1 adult study for VAX-A1 in mid-2026. Q1 R&D expense was $312.8 million and net loss was $320.6 million.
www.stocktitan.net
May 6, 2026 at 8:05 PM
#PCVX Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-1j4rsdh8blrl.html
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-first-quarter-2026-financial-results-and-provides-1j4rsdh8blrl.html
#PCVX Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-dgb8klnfr81t.html
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-dgb8klnfr81t.html
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Vaxcyte (Nasdaq: PCVX) reported second quarter 2026 results and pipeline progress. Cash, cash equivalents and investments totaled $2.51 billion at June 30, 2026, up from $2.44 billion at year-end 2025. R&D expenses were $267.9 million and G&A expenses were $34.9 million, leading to a quarterly net loss of $284.3 million, versus $166.6 million a year earlier.All three adult Phase 3 OPUS trials of VAX-31 are fully enrolled with 6,191 adults dosed, and topline OPUS-1 data are expected in Q4 2026, with OPUS-2 and OPUS-3 readouts in the first half of 2027. The VAX-31 infant Phase 2 study is fully enrolled, with topline primary series and booster data expected by the end of the first half of 2027. Vaxcyte also initiated a Phase 1 study of VAX-A1 for Group A Streptococcus, with topline data planned for the second half of 2027, and appointed vaccine industry veterans Moncef Slaoui and John Markels to its board.
www.stocktitan.net
August 5, 2026 at 8:05 PM
#PCVX Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-dgb8klnfr81t.html
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-second-quarter-2026-financial-results-and-provides-dgb8klnfr81t.html
📈 Score Movers (24h) · QCOM: 33/100 ▼3 pts (Low) · PCVX: 31/100 ▼3 pts (Low) · AAPL: 33/100 ▼3 pts (Low) · AXP: 49/100 ▼2 pts (Medium) · BIIB: 52/100 ▼2 pts (Medium) #investing #stocks #StockMarket
August 15, 2026 at 7:32 PM
📈 Score Movers (24h) · QCOM: 33/100 ▼3 pts (Low) · PCVX: 31/100 ▼3 pts (Low) · AAPL: 33/100 ▼3 pts (Low) · AXP: 49/100 ▼2 pts (Medium) · BIIB: 52/100 ▼2 pts (Medium) #investing #stocks #StockMarket
Breaking News: ( NASDAQ: #PCVX ) Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
#StockMarket #News
#StockMarket #News
September 3, 2024 at 2:10 PM
I’ve recently published Under The Shadow Of Words, an on-line poetry book that I would like to share with you. You’re invited to read it.
By the way it’s free and truly hope that you enjoy it. The link is: online.fliphtml5.com/jwxyt/pcvx/
By the way it’s free and truly hope that you enjoy it. The link is: online.fliphtml5.com/jwxyt/pcvx/
Under the Shadow of Words
Under the Shadow of Words<br>In this edition I offer you poems about justice, freedom, war, love, longing, hope and others that came out of a whim. I hope you enjoy them.<br><br>Bajo la Sombra de Pala...
online.fliphtml5.com
May 17, 2024 at 9:18 PM
I’ve recently published Under The Shadow Of Words, an on-line poetry book that I would like to share with you. You’re invited to read it.
By the way it’s free and truly hope that you enjoy it. The link is: online.fliphtml5.com/jwxyt/pcvx/
By the way it’s free and truly hope that you enjoy it. The link is: online.fliphtml5.com/jwxyt/pcvx/
Thoughts on this? >> Vaxcyte's Phase 2 pneumococcal vaccine data disappoint
investors >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical
investors >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical
Vaxcyte's Phase 2 pneumococcal vaccine data disappoint
investors
Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine in infants. The company said VAX-24 was non-inferior to Pfizer' ...
dlvr.it
March 31, 2025 at 7:46 PM
Thoughts on this? >> Vaxcyte's Phase 2 pneumococcal vaccine data disappoint
investors >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical
investors >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical
After closing Tuesday's session at $110.15 (up 36% on pneumococcal vax results), Vaxcyte proposed to raise $1b in a follow-on. It priced the upsized offering Wednesday night at $103 (6% discount) to raise $1.3b. www.globenewswire.com/news-release...
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
www.globenewswire.com
September 5, 2024 at 12:08 PM
After closing Tuesday's session at $110.15 (up 36% on pneumococcal vax results), Vaxcyte proposed to raise $1b in a follow-on. It priced the upsized offering Wednesday night at $103 (6% discount) to raise $1.3b. www.globenewswire.com/news-release...
With the full exercise of the underwriters' option, Vaxcyte's follow-on comes in just under $1.5 billion, making it the largest such deal thus far in 2024. The offering closely follows Tuesday's readout for the company's pneumococcal conjugate vaccine. www.globenewswire.com/en/news-rele...
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
www.globenewswire.com
September 6, 2024 at 9:31 PM
With the full exercise of the underwriters' option, Vaxcyte's follow-on comes in just under $1.5 billion, making it the largest such deal thus far in 2024. The offering closely follows Tuesday's readout for the company's pneumococcal conjugate vaccine. www.globenewswire.com/en/news-rele...
Rep. Gilbert Cisneros (D-CA) disclosed 15 trades:
Traded: Jul 16 | Disclosed: Sep 4
Bought: #COMP, #AORT, #PCVX, #SFM, #SKWD, #HLI, #FERG, #EPAC, #CSW
Sold: #SPXC, #SMTC, #RBC, #MTSI, #LAMR, #FN
https://integrityindex.us/candidate/gil-cisneros
Traded: Jul 16 | Disclosed: Sep 4
Bought: #COMP, #AORT, #PCVX, #SFM, #SKWD, #HLI, #FERG, #EPAC, #CSW
Sold: #SPXC, #SMTC, #RBC, #MTSI, #LAMR, #FN
https://integrityindex.us/candidate/gil-cisneros
Gilbert Cisneros - Integrity Index
View Gilbert Cisneros's political integrity grade, campaign financing, and conflicts of interest.
integrityindex.us
September 8, 2026 at 4:01 PM
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - BeyondLink
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The
beyondlink.live
September 6, 2026 at 2:32 PM
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
🚨 $PCVX
8-K Analysis Error: HTTPSConnectionPool(host='www.sec.gov', port=443): Read timed out. (read timeout=10)
8-K Analysis Error: HTTPSConnectionPool(host='www.sec.gov', port=443): Read timed out. (read timeout=10)
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
September 3, 2026 at 8:20 PM
🚨 $PCVX
8-K Analysis Error: HTTPSConnectionPool(host='www.sec.gov', port=443): Read timed out. (read timeout=10)
8-K Analysis Error: HTTPSConnectionPool(host='www.sec.gov', port=443): Read timed out. (read timeout=10)